Ireland-headquartered Actavis (NYSE: ACT) has been granted an exclusive option to acquire USA-based biopharma company Rhythm Pharmaceutical's wholly-owned subsidiary, Rhythm Health Inc, which is developing relamorelin (RM-131), a peptide ghrelin agonist, for the treatment of diabetic gastroparesis and other gastro-intestinal (GI) functional disorders.
Rhythm has completed a successful Phase II trial of relamorelin for the treatment of diabetic gastroparesis and a second successful Phase II study for chronic constipation. Rhythm expects to initiate a Phase IIb clinical trial for the treatment of diabetic gastroparesis by early 2015.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze